Additional Abilities Fortify CDMO Offerings
GEORGETOWN, Texas, May perhaps 09, 2023–(Company WIRE)–AustinPx, a deal improvement and production corporation (CDMO) specializing in analytical and formulation progress providers and cGMP production for tiny molecule medications, nowadays announced the expansion of its abilities to meet marketplace demand from customers for the Company’s expert services and skills. The Business has additional new spray drying and encapsulation abilities and has also expanded its GMP manufacturing capacity for higher shear and fluid bed granulation.
AustinPx has put in and validated a Dott. Bonapace INCAP capsule filler, a Freund-Vector VFC3 product fluid bed, and a Freund-Vector GMXB-Pilot design granulator. The INCAP rounds out the Company’s solid dose production capabilities, although the fluid mattress and granulator dietary supplement the Company’s producing scale.
“The investments are a critical ingredient of AustinPx’s much larger technique to extend our oral dose enhancement and manufacturing capabilities to improved serve our clients’ escalating need,” claimed Justin Eager, PhD, senior vice president functions. “The additions reveal our ongoing motivation to offering our purchasers with the very best attainable support and assistance.”
In line with the Company’s mission of giving science-driven formulation enhancement, AustinPx has put in a PROCEPT modular 4M8-Trix for the growth of spray dried amorphous reliable dispersions. The addition health supplements AustinPx’s present-day portfolio of bioavailability enhancement systems, like KinetiSol® Technologies – the Company’s proprietary fusion-centered amorphous dispersion production platform.
“We are excited to add spray drying to our portfolio,” said Dave Miller, PhD, chief scientific officer. “When combined with our present formulation capabilities, the addition enables us to offer a comprehensive suite of bioavailability enhancement alternatives to recognize the ideal formulation pathway for improperly soluble compounds and deal with a bigger number of our clients’ issues.”
The expanded capabilities are now available for use. These additions are the initial of quite a few strategic investments planned for the Enterprise in the quick future, as AustinPx carries on to place by itself as a major CDMO in the pharmaceutical marketplace.
About AustinPx
AustinPx, Pharmaceutics and Producing, is a agreement advancement and producing firm (CDMO) supplying analytical and formulation enhancement companies and cGMP production for tiny molecule prescription drugs. We specialize in section-proper enhancement methods, pace to clinic and marketplace tactics, and bioavailability enhancement of badly soluble molecules – together with our upcoming technology amorphous dispersion system, KinetiSol® Engineering. For far more info, www.AustinPx.com.
See source variation on businesswire.com: https://www.businesswire.com/news/dwelling/20230509006187/en/
Contacts
Elizabeth Hickman
Chief Enterprise Officer
ehickman@austinpx.com
512-686-4740
AustinPx.com
